chemotherapy

Germany’s Merck Ends Bavencio Pact with Pfizer

Germany’s Merck will regain exclusive worldwide rights to develop, manufacture and commercialize the anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of its Alliance agreement with US drugs giant Pfizer, planned for the end of the second quarter.

Genentech Returns Cancer Drug Rights to NewLink

FDA Approves NuvOx IND Brain Tumor Trial

China Gets its First Generic Geftinib Drug

FDA Halts Cancer Trial After Deaths

Genentech’s Bladder Cancer Drug Wins US Approval

FDA Approves New Pancreatic Cancer Treatment

EU Approves Pfizer-Hospira Deal With Strings

More Pressure to Justify Cost of Cancer Drugs Versus Benefits

Manufacturing of HPAPIs and ADC Toxins for the Drugs of Tomorrow